Ishares Msci Thailand Etf vs Zimmer Biomet Holdings Inc — how do they compare? Ishares Msci Thailand Etf trades at $72.91, while Zimmer Biomet Holdings Inc trades at $97 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while Ishares Msci Thailand Etf pays none, and Ishares Msci Thailand Etf is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| THD | ZBH | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $75.05 | $107.71 |
52-Week Low | $56.41 | $79.58 |
Market Cap | — | $18.55B |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
THD trades at $73.63, up 1.03% for the day, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The stock has shown strong performance, driven by exposure to AI hardware plays like Delta Electronics, contributing to its 38% total returns over the past year, as noted by Seeking Alpha on July 9, 2026. A dividend of $1.71 is scheduled for June 2026, adding income potential.
Outlook remains positive due to AI-driven growth, but risks include vulnerability to semiconductor sector volatility and foreign capital outflows from Asian equities. Investors should weigh the bullish technicals against macroeconomic uncertainties in the region for balanced exposure.
No Aura AI signal available yet.
Trailing returns across standard periods
THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →